EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden

Mahasin Al Shakirchi iD, Kimmo Sorjonen, Lena Hjelte, Lena Klingspor, Peter Bergman, Petrea Ericson, Marcus Svedberg, Ulrika Lindberg, Christine Hansen, Isabelle de Monestrol

Therapeutic Advances in Respiratory Disease · 2024

DOI: 10.1177/17534666241254090 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von Mahasin Al Shakirchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Department of Clinical Science, Intervention and Technology, Sweden. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Drug Combinations. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärt-Lungfonden, Stiftelsen Riksförbundet Cystisk Fibros Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A significant decline in pulmonary exacerbation rates has been reported in CF patients homozygous for F508del treated with lumacaftor/ivacaftor. However, it is still unclear whether this reduction reflects a diminished microbiological burden.

Objectives

The aim of this study was to determine the impact of lumacaftor/ivacaftor on the bacterial and fungal burden.

Design

The study is a prospective multicenter cohort study including 132 CF patients homozygous for F508del treated with lumacaftor/ivacaftor.

Methods

Clinical parameters as well as bacterial and fungal outcomes 1 year after initiation of lumacaftor/ivacaftor were compared to data from 2 years prior to initiation of the treatment. Changes in the slope of the outcomes before and after the onset of treatment were assessed.

Results

Lung function measured as ppFEV1 ( p < 0.001), body mass index (BMI) in adults ( p < 0.001), and BMI z-score in children ( p = 0.007) were improved after initiation of lumacaftor/ivacaftor. In addition, the slope of the prevalence of Streptococcus pneumoniae ( p = 0.007) and Stenotrophomonas maltophilia ( p < 0.001) shifted from positive to negative, that is, became less prevalent, 1 year after treatment, while the slope for Candida albicans ( p = 0.009), Penicillium spp ( p = 0.026), and Scedosporium apiospermum ( p < 0.001) shifted from negative to positive.

Conclusion

The current study showed a significant improvement in clinical parameters and a reduction of some of CF respiratory microorganisms 1 year after starting with lumacaftor/ivacaftor. However, no significant changes were observed for Pseudomonas aeruginosa, Staphylococcus aureus, or Aspergillus fumigatus, key pathogens in the CF context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesDrug CombinationsAminopyridinesQuinolonesHumansMaleProspective StudiesFemaleChildAdultYoung AdultAdolescentSwedenTreatment OutcomeMycosesRespiratory Tract InfectionsCystic Fibrosis Transmembrane Conductance RegulatorLungChloride Channel AgonistsTime FactorsFungiBacterial Infections

Stichwörter der Autor:innen

bacteriacystic fibrosisfungilumacaftor/ivacaftor

Substanzen

AminophenolsBenzodioxolesDrug CombinationsAminopyridineslumacaftor, ivacaftor drug combinationQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, humanChloride Channel Agonists

Autor:innen und Institutionen

  • Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Department of Clinical Science, Intervention and Technology, Sweden.
  • Division of Pediatrics, Karolinska Institutet, Alfred Nobels Allé 8, Stockholm 171 77, Sweden.
  • Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Stockholm, Sweden.
  • Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Mahasin Al Shakirchi

Förderung

  • Hjärt-Lungfonden
  • Stiftelsen Riksförbundet Cystisk Fibros Forskningsfond

Zitieren

APA

Al Shakirchi, M., Sorjonen, K., Hjelte, L., Klingspor, L., Bergman, P., Ericson, P., Svedberg, M., Lindberg, U., Hansen, C., & Monestrol, I. (2024). Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241254090

Vancouver

Al Shakirchi M, Sorjonen K, Hjelte L, Klingspor L, Bergman P, Ericson P, et al. Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241254090

BibTeX
@article{AlShakirchi2024,
  author = {Al Shakirchi, Mahasin and Sorjonen, Kimmo and Hjelte, Lena and Klingspor, Lena and Bergman, Peter and Ericson, Petrea and Svedberg, Marcus and Lindberg, Ulrika and Hansen, Christine and Monestrol, Isabelle de},
  title = {Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  doi = {10.1177/17534666241254090}
}
Kostenlos starten →